title: Reduced body weight, adipose tissue, and leptin levels despite increased energy intake in female mice lacking acylation-stimulating protein.
abstract: Acylation-stimulating protein (ASP) is a potent lipogenic protein produced by adipocytes. In vitro studies have shown that ASP increases triglyceride synthesis and glucose transport in both murine and human adipocytes. Our initial study indicated that complement C3-deficient (-/-) mice (and, therefore, ASP deficient) demonstrated altered dietary postprandial triglyceride clearance. In the present study we examined the phenotype of female mice longitudinally on different diets. Female C3(-/-) mice on both low (10% of energy) and high (40% of energy) fat diets displayed an average reduction in total body weight of 10.1+/-0.5% (P < 0.0003, by ANOVA) compared with the C3(+/+) littermates. Reductions in white adipose tissue mass accounted for most of this weight difference (59% reduction; P < 0.01 on low fat diet). Plasma leptin levels were significantly reduced in C3(-/-) mice on both high (P < 0.001) and low fat diets (P < 0.01). This reduction was significant even after adjusting for the reduced body weight and body fat (P < 0.001). Leptin reductions in the C3(-/-) were greater on the high fat diet and were associated with increased food intake (18+/-2% increase; P < 0.001). Furthermore, there was a decrease in basal glucose levels and basal insulin levels [12.8% decrease in glucose at 14 weeks (HF; P < 0.05) and 41% decrease in insulin at 26 weeks (HF; P < 0.05)]. These in vivo experiments demonstrate that female mice lacking ASP have marked alterations of body weight, adiposity, plasma leptin, and plasma insulin levels. Decreased adiposity and leptin levels occurred in the ASP-deficient animals despite increased energy intake, suggesting that energy expenditure was elevated in these animals. Thus, ASP appears to have an important role in the regulation of energy balance in mice.
authors.affiliation: Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Center, Montréal, Québec, Canada.
authors.forename: I
authors.initials: I
authors.lastname: Murray
authors.forename: P J
authors.initials: PJ
authors.lastname: Havel
authors.forename: A D
authors.initials: AD
authors.lastname: Sniderman
authors.forename: K
authors.initials: K
authors.lastname: Cianflone
mesh_terms: D000273:Adipose Tissue / Q000254:growth & development / Q000502:physiology*; D000818:Animals; D019540:Area Under Curve; D001798:Blood Proteins / Q000096:biosynthesis* / Q000172:deficiency* / Q000235:genetics; D001835:Body Weight / Q000502:physiology*; D015926:Complement C3a / Q000031:analogs & derivatives*; D004032:Diet; D004435:Eating / Q000502:physiology; D004734:Energy Metabolism / Q000502:physiology*; D005243:Feces / Q000737:chemistry; D005260:Female; D005838:Genotype; D005947:Glucose / Q000494:pharmacology; D005951:Glucose Tolerance Test; D020738:Leptin / Q000378:metabolism*; D051379:Mice; D018345:Mice, Knockout; D009929:Organ Size / Q000502:physiology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014280:Triglycerides / Q000097:blood
chemical_list: D001798:Blood Proteins; D020738:Leptin; D014280:Triglycerides; C044541:complement C3a, des-Arg-(77)-; D015926:Complement C3a; D005947:Glucose